RxDoctor Payments Data

Kaitlin Rogge

Nurse Practitioner · Lincoln, NENPI 1063196707

Payments from drug & device makers

$1,208in general payments, 2019–2025

Across 47 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$175
  • Corcept Therapeutics$156
  • AbbVie$132
  • Actelion Pharmaceuticals US, Inc.$121
  • Exact Sciences$68
  • Astellas Pharma US Inc$62
  • plus $494 from 18 others

What the payments were for

  • Food & beverage$1,11993%
  • Education$907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,208 in reported general payments places this provider in the 75th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$16,925
Medicare patients
68
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib20$773
Omeprazole27$696
Atorvastatin Calcium58$580
Levocetirizine Dihydrochloride16$464
Bupropion XlBupropion Hcl23$441
Gabapentin18$360
Montelukast Sodium23$349
Hydroxyzine Hcl15$337
Venlafaxine Hcl ErVenlafaxine Hcl27$319
Potassium Chloride25$280
Fluticasone Propionate25$231
Dicyclomine Hcl15$227
Albuterol Sulfate HfaAlbuterol Sulfate13$212
Lisinopril39$183
Amlodipine Besylate29$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$17$5516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →